Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Rewind Therapeutics logo — Pioneering novel treatments for neurological diseases, advan...

Rewind Therapeutics

Pioneering novel treatments for neurological diseases, advancing the way to effective remyelination for multiple sclerosis and myelin-related conditions.

Founded 2017 2-10 employees Series A Total: $18.10M Biotechnology, Health and Wellness

General Information

Company Name Rewind Therapeutics
Founded Year 2017
Employees 2-10
Industries Biotechnology, Health and Wellness
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Rewind Therapeutics. To contact Rewind Therapeutics, visit rwdtx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Rewind Therapeutics compare?

A PDF of Rewind Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Rewind Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Rewind Therapeutics

Rewind Therapeutics is a biotechnology startup founded in 2017, dedicated to pioneering novel treatments for neurological diseases. The company's innovative approach focuses on advancing the way to effective remyelination for multiple sclerosis and myelin-related conditions. By employing first-in-class remyelinating therapeutics, Rewind Therapeutics inhibits signals that restrict the expansion and migration of oligodendrocyte stem cells, thus promoting effective remyelination. This breakthrough technology offers a promising avenue for medical practitioners to more efficiently treat patients suffering from multiple sclerosis and other myelin-related diseases. The company's recent Series A investment at 25 January 2023 drew attention from a diverse group of investors including Sunstone Capital, MERL Ventures Fund, PMV, Gemma Frisius Fund, Centre for Drug Design & Discovery (CD3), Boehringer Ingelheim Venture Fund. With its focus on disrupting the biotechnology and health and wellness industries, Rewind Therapeutics shows significant potential for addressing critical unmet medical needs.

Business keywords: Neurological diseases, Remyelination, Therapeutics, Oligodendrocyte stem cells, Multiple sclerosis, Myelin-related conditions, Biotech, Innovative therapies, Medical advancements, Treatment development

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Undisclosed 6
Sunstone Capital MERL Ventures Fund PMV
Sunstone Capital, MERL Ventures Fund +4
25 Jan 2023
Grant €2.90M 1
Agentschap Innoveren & Ondernemen
01 Aug 2019
Series A €15.20M 3
MERL Ventures Fund
MERL Ventures Fund, Boehringer Ingelheim Venture Fund +1
04 Jan 2018

Rewind Therapeutics Alternatives & Competitors

View All Alternatives
Rewind Therapeutics vs
Novoron Bioscience
Novoron Bioscience United States

Pioneering lipoprotein-receptor drug development to repair damage and degeneration to the brain, spi...

Seed
17 employees
Biopharma, Biotechnology
Rewind Therapeutics vs
Disarm Therapeutics
Disarm Therapeutics

Creating advanced therapeutics to combat axonal degeneration and treat neurological diseases since 2...

Series A
Biotechnology, Health Care
Rewind Therapeutics vs
Celltex Therapeutics Corporation
Celltex Therapeutics Corporation United States

A Houston-based biotech company focused on breakthroughs using autologous, adipose-derived Mesenchym...

Venture round
33 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Rewind Therapeutics

Pioneering novel treatments for neurological diseases, advancing the way to effective remyelination for multiple sclerosis and myelin-related conditions.
Rewind Therapeutics was founded in 2017.
Rewind Therapeutics operates in Biotechnology and Health and Wellness. Its work centres on Neurological diseases, Remyelination, Therapeutics and Oligodendrocyte stem cells.
Rewind Therapeutics has approximately 2-10 employees.
Rewind Therapeutics has completed 3 funding rounds, raising a total of $18.10M. The latest funding stage is Series A.
Top alternatives and competitors to Rewind Therapeutics include Novoron Bioscience, Disarm Therapeutics, Celltex Therapeutics Corporation, GliaCure, Celularity Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Rewind Therapeutics and Novoron Bioscience are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Rewind Therapeutics, https://bouncewatch.com/company/rewind-therapeutics, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes